European Primary Care Cardiovascular Society

More out-of-hospital cardiac arrest during COVID-19 outbreak in Lombardy, Italy

3' education - June 18, 2020 - Enrico Baldi, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - May 14, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

COVID-19, ACE2 and RAASi - a clinical perspective

10' education - May 14, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A call to collect data on CV variables in patients with COVID-19

3' education - Apr. 14, 2020 - Prof. Folkert Asselbergs, MD, PhD

Rate of smoking cessation higher with e-cigarettes compared to counseling

3' education - Apr. 13, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Mechanistic evidence of CV benefit observed with icosapent ethyl

3' education - Apr. 12, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

Reliable results with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Apr. 9, 2020 - Prof. Deepak Bhatt, MD

Significant reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 8, 2020 - Prof. Frederick Raal, PhD - ACC 2020

Better insight into current daily clinical practice and more collaboration is needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu

Why we need updated Diabetes Guidelines and new recommendations

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Policy recommendations to stimulate implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Cornelia Bala - European Diabetes Policy Summit

Implementation of guidelines: identifying barriers

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Old anti-inflammatory drug successfully repurposed for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, Boston - AHA 2019, Philadelphia

Anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Dec. 19, 2019 - Jean-Claude Tardif, Montreal - AHA 2019, Philadelphia

SGLT2i gives consistent CV benefit and tolerability in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, Glasgow - AHA 2019, Philadelphia

Fish oil may give favorable effects on plaque-parameters

3' education - Nov. 17, 2019 - Stephen Nicholls, Melbourne - AHA 2019, Philadelphia

Reduction of antihypertensive medication noninferior to usual care in elderly

Literature - July 1, 2020 - Sheppard JP, et al. - JAMA 2020

Reduction of antihypertensive medication in patients ≥80 years who were on ≥2 antihypertensive medication was noninferior to usual care with regard to SBP control at 12 weeks.

FDA approval for P2Y12i to treat CAD patients without history of stroke or MI

News - July 1, 2020

The P2Y12 inhibitor ticagrelor has now been approved by the FDA to reduce risk of first MI or stoke in high-risk coronary artery disease (CAD) patients.

Comprehensive disease-modifying pharmacological therapies reduce CV events in HFrEF

Literature - July 1, 2020 - Vaduganathan M et al., - The Lancet. 2020.

This cross-trial analysis estimated that comprehensive disease-modifying pharmacological therapy in HFrEF patients reduces the hazard of CV death or hospital admission, compared with conventional therapy.

Risk of stroke not increased in AF patients without CV comorbidities

Literature - July 1, 2020 - Singleton MJ et al., - J Am Heart Assoc. 2020

This analysis of the REGARDS study showed that AF patients without CV comorbidities had no increased risk of stroke compared to individuals without AF or CV comorbidities.

More out-of-hospital cardiac arrest during COVID-19 outbreak in Lombardy, Italy

3' education - June 18, 2020 - Enrico Baldi, MD
There was a 58% increase in out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak in the Lombardia region in Italy compared to the same period in 2019. Watch a video on the study by Baldi and colleagues.

Out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak was substantially increased in the Lombardia region in Italy compared to the same period in 2019. Baldi briefly presents the details and outcomes of a study.

An 11-item questionnaire to screen for AF, HF, and CAD in primary care

Literature - June 16, 2020 - Zwartkruis VW et al., - Prev Med. 2020.

A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis
A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.

A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.

Issues of CV risk management in diabetes patients during the COVID-19 era

News - June 2, 2020

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

Differences between men and women in CV medication prescription prevalence in primary care

Literature - June 2, 2020 - Zhao M et al., - J Am Heart Assoc. 2020.

This systematic review and meta-analysis of 43 studies showed that the prescription prevalence in women was lower for aspirin, statins, and ACE inhibitors, but higher for diuretics, compared to men.

HF and CKD most frequent first CV- and renal disease manifestations in T2D

Literature - June 2, 2020 - Birkeland KI et al., - Diabetes Obes Metab. 2020.

This study showed that the most frequent first manifestations of CV- and renal disease in T2D patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.

Drinking filtered coffee associated with lower mortality

Literature - June 2, 2020 - Tverdal A et al., - Eur J Prev Cardiol. 2020.

A large Norwegian cohort study showed that drinking filtered coffee was associated with lower mortality than no coffee, while no association between coffee drinking and mortality was observed for those drinking unfiltered coffee.

Novel selective cardiac myosin activator in HF gets FDA Fast Track designation

News - June 2, 2020

Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.